Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fred Grynberg

Pulmonary Disease Miami, FL Medical Doctor

NPI 1083600803 CMS profile 185328

1190 Nw 95Th St Ste 108, Ste 401, Miami, FL 33150

Open in the dashboard

General payments

$10,235

156 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,434 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Fred Grynberg of Miami, FL is reported in the CMS Open Payments database as having received $10,235 across 156 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,434 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,654 27
2024 General $1,681 27
2023 General $3,982 24
2022 General $611 16
2021 General $624 23
2020 General $479 20
2019 General $1,205 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fred Grynberg
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Fred Grynberg were reported at $1,654. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Fred Grynberg Pulmonary Disease median Middle half National median
2019 $1,205 $377 $109–$1,340 $163
2020 $479 $230 $56–$907 $114
2021 $624 $269 $68–$1,072 $132
2022 $611 $390 $100–$1,457 $149
2023 $3,982 $419 $114–$1,659 $160
2024 $1,681 $476 $123–$1,818 $164
2025 $1,654 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Chiesi USA, Inc. $2,995 5 payments
  2. GlaxoSmithKline, LLC. $2,592 77 payments
  3. AstraZeneca Pharmaceuticals LP $2,193 33 payments
  4. Insmed, Inc. $964 18 payments
  5. Genzyme Corporation $423 6 payments
  6. United Therapeutics Corporation $305 2 payments
  7. Harmony Biosciences LLC $228 2 payments
  8. Inspire Medical Systems, Inc. $158 1 payment
  9. ANI Pharmaceuticals, Inc. $125 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $67 2 payments
  11. Other $186 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,735 147 payments
  2. Travel and Lodging $2,288 2 payments
  3. Education $212 7 payments
Products named General payments · program years 2019–2025
  1. Arikayce $851 17 payments
  2. AREXVY $763 10 payments
  3. NUCALA $743 22 payments
  4. TRELEGY ELLIPTA $682 39 payments
  5. FASENRA Respiratory $545 8 payments
  6. FASENRA Respiratory $489 10 payments
  7. BREZTRI $410 6 payments
  8. AIRSUPRA $371 3 payments
  9. TEZSPIRE $355 5 payments
  10. DUPIXENT $311 5 payments
  11. Other $1,440 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

655

Median for Pulmonary Disease: 936

Drug cost

$243,528

Median for Pulmonary Disease: $487,987

Branded share of claims

64.1%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 124 $89,396
Nucala Mepolizumab Brand 18 $67,117
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 63 $41,698
Ozempic Semaglutide Brand 17 $14,353
Breo Ellipta Fluticasone/Vilanterol Brand 11 $5,868
Spiriva Respimat Tiotropium Bromide Brand 12 $5,681
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 12 $5,578
Symbicort Budesonide/Formoterol Fumarate Brand 13 $4,750
Albuterol Sulfate Hfa Albuterol Sulfate Brand 111 $2,702
Breyna Budesonide/Formoterol Fumarate Brand 15 $2,426

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$64,494

Medicare's payments for the services billed

Medicare patients

99

Average age 73

Services billed

862

39 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Ischemic heart disease 55%
COPD 51%
Depression 49%
Chronic kidney disease 44%
Heart failure 41%
Arthritis 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $482
$482 — —
WAKIX
  • Harmony Biosciences LLC $228
$228 — —
TYVASO
  • United Therapeutics Corporation $148
$148 — —
Arikayce
  • Insmed, Inc. $139
$139 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record